The market for Pharmaceutical Intermediates Market is expected to reach USD$ 36,890.6 Mn in 2027.
The pharmaceutical intermediates market is set to grow from US$ 25,965.0 million in 2018 to US$ 36,890.6 million by 2027 at a compound annual growth rate (CAGR) of 4.0% during the forecast period from 2019 to 2027. A significant rise in drug formulation and research activities and a supportive regulatory environment provided by global healthcare agencies will consolidate the pharmaceutical intermediates market during the forecast period.
Bulk drug intermediates are the dominant product segment in the pharmaceutical intermediates market. The key driver associated with its market growth is the significant rise in drug formulation research and development (FR&D).
They are used as raw material in the manufacturing of bulk drugs or as a secondary product generated during the synthesis of an active pharmaceutical ingredient (API), having the potential to be used in various drug formulations. Custom intermediates are gaining huge traction on account of increased drug development and research activities and the burgeoning requirement for novel medicines to treat orphan diseases.
Pharmaceutical and biotechnology companies are spearheading the end-user segment for the pharmaceutical intermediates market. The key drivers associated with its dominating market growth are the rising prevalence of life-threatening diseases and the stringent regulatory norms pertaining to cGMP and cGLP guidelines for drug manufacturing imposed by healthcare agencies worldwide.
Research laboratories have shown impressive growth in the last two decades on account of increasing demand for pharmaceutical intermediates in developing novel medicines for treating rare and autoimmune diseases. Contract manufacturing organizations will highlight rampant growth during the forecast period on account of increasing demand for generic medicines due to the patent expiration of blockbuster drugs in the near future and a significant rise in drug manufacturing outsourcing activities to penetrate untapped markets worldwide.
North America presently holds 35.8% market growth and is the largest regional segment for the pharmaceutical intermediates market. The drivers responsible for its positive market growth are the presence of a well-developed healthcare infrastructure and rising public health awareness. Europe is placed second in the regional segment, representing 30.4% of the market, on account of a significant rise in the patient population seeking medical intervention for life-threatening diseases and the supportive regulatory environment provided by the European Medical Agency (EMA) for the pharmaceutical intermediates market.
Asia Pacific is accountable for 20.2% of the market share owing to proactive government policies resulting in flourishing drug manufacturing activities and serves as a lucrative market opportunity for western giants to enter into strategic collaboration and agreements with local players owing to the flourishing generic drug market in the Asia Pacific region.
This research report presents the analysis of each segment from 2017 to 2027, considering 2018 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2019 to 2027.
Companies producing pharmaceutical intermediates are BASF SE, Bristol-Myers Squibb Company, Cambrex Corporation, Chiracon GmbH, Codexis, Inc., Dishman Group, Dextra Laboratories, Ltd., Lonza, Midas Pharma GmbH, Vertellus Holdings LLC.
The market for Pharmaceutical Intermediates Market is expected to reach USD$ 36,890.6 Mn in 2027.
The Pharmaceutical Intermediates Market is expected to see significant CAGR growth over the coming years, at 4.0%.
The report is forecasted from 2019 -2027.
The base year of this report is 2018.
Cambrex Corporation, Chiracon GmbH, Codexis, Inc., Dishman Group, Dextra Laboratories, Ltd.are some of the major players in the global market.